The U.S. Supreme Court unanimously rejected a challenge to the Food and Drug Administration (FDA)’s authority to regulate mifepristone, a medication used in early abortion. The ruling is critical for providing continued access to mifepristone at a time when more people than ever face barriers to making their own choices about their health care since the overturning of Roe v. Wade. Patients can continue to receive the medicine by mail and at certified pharmacies.  

The ability to choose whether and when to have a child, to give birth safely, and to raise children in a supportive environment is essential to living a healthy, empowered life and foundational to a just and equitable society.  

The Packard Foundation has a long history of investments to bring safe, affordable contraceptives and medical abortion pharmaceuticals, including mifepristone, to market. We will continue our work with partners across the country to support innovation and ensure that people have access to affordable, quality reproductive health options, including abortion care.